Key result
Cardiac contractility modulation fails to reduce mortality or HF hospitalizations vs optimal medical therapy.
Why the study?
Cardiac contractility modulation is a device therapy for systolic HF with narrow QRS, but an updated assessment of its efficacy and safety in RCTs was needed.
Does cardiac contractility modulation reduce mortality and hospitalizations or improve functional status in adult patients with systolic heart failure and narrow QRS?
Meta-Analysis (n=801)
Does cardiac contractility modulation reduce mortality and hospitalizations or improve functional status in adult patients with systolic heart failure and narrow QRS?
Answers are grounded in this paper and cite their sources.
Cardiac contractility modulation offers short-term improvements in quality of life for patients with systolic heart failure and a narrow QRS, but current evidence does not demonstrate a reduction in mortality or hospitalizations.
BACKGROUND: Cardiac contractility modulation (CCM) is a device therapy for systolic heart failure (HF) in patients with narrow QRS. We aimed to perform an updated meta-analysis of the randomized clinical trials (RCTs) to assess the efficacy and safety of CCM therapy. METHODS: We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) between January 2001 and June 2018. Outcomes of interest were peak oxygen consumption (peak VO2), 6-Minute Walk Distance (6MWD), Minnesota Living with Heart Failure Questionnaire (MLHFQ), HF hospitalizations, cardiac arrhythmias, pacemaker/ICD malfunctioning, all-cause hospitalizations, and mortality. Data were expressed as standardized mean difference (SMD) or odds ratio (OR). RESULTS: Four RCTs including 801 patients (CCM n = 394) were available for analysis. The mean age was 59.63 ± 0.84 years, mean ejection fraction was 29.14 ± 1.22%, and mean QRS duration was 106.23 ± 1.65 msec. Mean follow-up duration was six months. CCM was associated with improved MLWHFQ (SMD -0.69, p = 0.0008). There were no differences in HF hospitalizations (OR 0.76, p = 0.12), 6MWD (SMD 0.67, p = 0.10), arrhythmias (OR 1.40, p = 0.14), pacemaker/ICD malfunction/sensing defect (OR 2.23, p = 0.06), all-cause hospitalizations (OR 0.73, p = 0.33), or all-cause mortality (OR 1.04, p = 0.92) between the CCM and non-CCM groups. CONCLUSIONS: Short-term treatment with CCM may improve MLFHQ without significant difference in 6MWD, arrhythmic events, HF hospitalizations, all-cause hospitalizations, and all-cause mortality. There is a trend towards increased pacemaker/ICD device malfunction. Larger RCTs might be needed to determine if the CCM therapy will be beneficial with longer follow-up.
No takes yet. Share an insight, caveat, or question.
Mando et al. (2019) conducted a meta-analysis in Systolic heart failure with narrow QRS (n=801). Cardiac contractility modulation vs. Optimal medical therapy was evaluated on All-cause mortality (OR 1.04, 95% CI 0.47 to 2.31, p=0.92). Cardiac contractility modulation did not reduce all-cause mortality or heart failure hospitalizations compared to optimal medical therapy, although it improved quality of life.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: